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Summary 
 
Mental and brain disorders represent  the greatest health burdens to Europe - not only for directly 
affected individuals, but also for caregivers and wider society. They incur substantial economic costs 
through direct (and indirect) healthcare and welfare spending, and via productivity losses - all of 
which significantly affect European development. Funding for research to mitigate these effects lags 
far behind the cost to society.  
 
We describe a comprehensive, coordinated mental health research agenda for Europe and the 
world. This was based on systematic literature reviews and consensus decision-making by 
multidisciplinary scientific experts and affected stakeholders (more than 1000 in total): individuals 
with mental health problems and their families, healthcare workers, policymakers and funders.  
We generated 6 priorities that will, over the next 5-10 years, help to close the most significant gaps 
in mental health research in Europe, and in turn overcome the substantial challenges we face as a 
result of mental disorders.  
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Mental Health Costs and Burdens 
There is a strong need for parity in service provision and research between mental and physical 
disorders. Mental and brain disorders represent the single largest contributor to disease burden in 
Europe1. More than one in three Europeans experience mental health problems in any given year1 
and even more will be affected indirectly – including family members, health systems and wider 
society. The increasing age of the European population means that the long term mental health 
burden is greater now than it has ever been2. The most recent estimate of yearly costs for mental 
disorders in Europe is €461 billion, as of 20103 – excluding any costs of dementia and other 
neurological disorders. Beyond direct costs to health services, this figure is largely due to indirect 
costs to social welfare, employment, well-being and economic output.  These costs are not 
decreasing. For instance, disability benefits in the UK and Germany have been relatively stable but 
the proportion accounted for by mental health disorders continues to rise4,5.  
A shorter life: People with a mental health problem experience earlier death6 by as much as 20 years7. 
This may be due to increased risk for physical health problems such as cardiovascular disease8 or 
because individuals with mental health problems do not seek early treatment for either their mental 
or physical health9. To go with evidence of early mortality is the shocking statistic that in Europe an 
estimated 1·5 million people attempt suicide each year, and 100,000 complete it10. In England and 
Wales it is the top cause of death for women and men aged 20-34, as well as for men aged 35-4911, 
and is a leading cause of death among 19-30 year-old men in Europe and worldwide12.  
Beginning early: We know that most mental health problems are chronic and begin early in life (50% 
before the age of 15 and 75% before the age of 1813) and this is fuelling calls for interventions in 
childhood to avert the development of long term problems. However, we do not know which 
interventions would be best or which children are most at risk of developing long-term problems. 
Mental health problems increase other health costs: We are now also beginning to realise that the 
costs of care dramatically increase if individuals with physical disorders have a comorbid mental 
health problem so cost estimates are conservative because they do not take into account this 
comorbidity. For people with rheumatoid arthritis, the costs of care nearly double if they suffer from 
depression14 and for asthma the increase is 140%12. People with depression also face a higher risk of 
developing heart disease, and following a heart attack each additional depressive symptom that 
develops increases the risk of another heart attack by 15%15. Individuals with diabetes who develop 
a foot ulcer and also suffer from depression have a high early mortality rate (30% within 18 months), 
three times higher than in those without depression16. Treating mental health problems therefore 
has potential advantages to individuals and to health services by reducing costs, morbidity and 
mortality associated with a wide range of physical disorders, in addition to reducing the direct costs 
of mental disorders.  
As well as increased rates of mental disorder being associated with higher costs, there is also 
evidence that research into mental health has demonstrable positive effects. For example, the RAND 
Mental Health Retrosight project demonstrates that over 20 years  basic and clinical research 
developments related to schizophrenia (e.g. locating GABA-A receptors in the brain; early 
intervention research; trials of supported employment) have an beneficial impact on patient care as 
well as yielding positive wider social and economic effects17.  
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Investing in Mental Health Research 
A good return on investment: Funding mental health research generates good return on investment. 
For every pound spent on UK mental health research there is an estimated recurring £0·37 return 
per year, which is similar to the return for cardiovascular disorder research18 and cancer19. Giant 
steps have been made in research into the mechanisms and treatments needed to alleviate and 
understand cancer and cardiovascular disease and we have seen some dramatic changes 
subsequently to health services and lifestyle advice offered for these disorders. These changes 
produced the 20% decrease in mortality for cancer seen over the 20-year period ending in 201320. 
For mental health a boost in research investment could have similar large effects within a relatively 
short time, not only reducing the burdens on individuals and families but also reducing the costs of 
care and support in the longer term.  
Uneven research funding distribution: Public funding for mental health research in Europe is much 
lower than the population impact. In England, mental disorders cost between £7021 and £105 billion 
per year22,23, but only £115 million – which could be as low as a thousandth of the yearly cost of 
mental disorders – is invested in UK mental health research24.  For comparison, cancer research 
received over 4.5 times as much funding as mental health in 2011 (£521 million)25, despite cancer 
accounting for only 15·9% of the UK’s total disease burden, compared to 22·8% for mental 
disorders26.  
In France, mental disorders cost €108 billion per year, but only €25 million is allocated to psychiatry 
research23. Mental health research funding available at the European level is also disproportionally 
low compared to the impact of mental disorders on population health. Mental disorders account for 
between 1127 and 27%1 of the disability burden in Europe28,29, but receive less than 5% of the overall 
FP7 health research budget30,31. For national funding the figures are no more encouraging: the 
percentage of mental health compared to overall health research funding are 2% in France and 7% in 
the UK32. 
 
While physical health research can attract substantial third-sector funding, this is not the case for 
mental health. A recent analysis found that for every £1 that the UK government spent on funding 
research in circulatory problems, cancer and mental health, the research funding from charities was: 
£1·25, £2·75 and £0·000324 respectively. We suspect that this pattern is the same across Europe. 
With such low charitable investment, it will take years of campaign building to redress the gap in 
funding. In the meantime, substantial increases in government spending would help to bring funding 
for mental health research in line with the costs of mental health problems to society.  
Preventative research could be especially useful in offsetting the costs of mental disorders33, but this 
currently receives especially low levels of funding. For example only £4·5 million is spent on 
preventative mental health research in the UK, or 0·17-0·28% of the total UK yearly spend on health 
research24,34.   
Poised for action 
Europe is now well-placed to respond to the challenges it faces as a result of mental health 
problems. 
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Scientific advantage: Recently, we have seen ground-breaking advances in biological and brain 
sciences (biomarkers from ‘-omics’ research, developments in brain mapping such as the 
connectome, fast genome-wide association studies, high-throughput / next generation DNA 
sequencing), eHealth and technology (web-based treatments, mobile apps for monitoring 
symptoms), psychological therapies (use and implementation of Cognitive Behavioural Therapy) and 
research infrastructure (open access publication, European Research Networks)35. We need to take 
advantage of these developments to produce more evidence along the whole translational pipeline 
from biological mechanisms to clinical implementation and preventative interventions. This will 
allow us to deliver and promote better treatments. 
European research advantage: Europe’s diverse health systems with near-universal coverage offer 
the ability to collect ‘big data’, with access to health registers and oversight of paths to care36. 
Together these features produce rich and representative datasets not available elsewhere. An added 
advantage is that Europe is home to numerous initiatives for including individuals with mental health 
problems in the design and management of research37,38. Service user involvement improves 
research feasibility39, treatment acceptability and ease of transfer to the wider health system, and 
will only become more important over time.  
As a result, European research is singularly well-placed to address many challenges in mental health 
over the next five to ten years. This fact – as well as the need for research into the prevention of 
mental disorders – has been recognised by the European Parliament and European Commission40,41. 
All that is required is an agenda for action and that is the focus of this paper. 
 
A Comprehensive and Inclusive Priority Development Method 
ROAMER (ROAdmap for MEntal health and well-being Research in Europe42) was set up to develop 
the agenda for mental health research with immediate and longer term priorities. It covers the 
mental disorders named in the 2010 Global Burden of Disease study27, but not neurodegenerative 
disorders (e.g. Alzheimer's disease and other dementias)27. An overview of the organisation of the 
ROAMER project is given in Haro et al.43 
The ROAMER programme was carried out by multidisciplinary Work Packages and Advisory Boards 
that covered the broad spectrum of approaches to mental health research43 (see Table 1 for details). 
The areas covered by each of the work packages were decided by consensus in meetings of the 
ROAMER steering committee of scientific experts and advisory boards. Scientific work packages 
(work packages 4-8 and the Clinical Research Task Force) were complemented by the Stakeholder 
and Scientific Advisory Boards44, who provided input and direction across the entire course of the 
ROAMER project. Geographical mapping of types of mental health research (e.g. RCT, epidemiology) 
and of European capacity, funding and infrastructure were carried out. All groups were advised to 
take into account the European (not just national) perspectives in research, funding and societal 
needs, as well as  demographic changes occurring within Europe2,41 and gender aspects of mental 
disorders. 
[Table 1 about here] 
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There were two phases to the ROAMER process. The first phase provided a mapping and gapping 
report based on systematic literature reviews carried out by the scientific work packages and Work 
Package 245–48.  
We retrieved 70,761 articles and 28,188 were used in the final mapping which highlighted the 
volume of different kinds of mental health research conducted across Europe. For instance the UK is 
strong in clinical randomised controlled trials, Iceland leads genetic studies and Serbia is strong in 
stigma research. The systematic mappings were used together with expert workshops, consensus 
meetings, modified Delphi methods, and surveys to determine for each work package what major 
research advances across the globe had been achieved in the last 10 years and what further 
advances were needed to overcome extant gaps.  
In the second phase research priorities and advances needed were established from each work 
package and integrated across the programme: scientific papers43,44,48–52 provide detail on each work 
package. All research priorities were justified in consensus meetings on the basis of their: i) likely 
efficacy/effectiveness; ii) European impact and economic benefits; iii) deliverability and 
answerability in Europe; and iv) relevance to European strengths. This ensured all ROAMER output 
took account of social, political and economic contexts in Europe, as well as existing European 
infrastructure, while strongly representing stakeholder priorities.  
Over 125 non-duplicates priorities generated by the individual work packages were integrated into a 
single list of 20. Feedback via a survey was gathered on these 20 priorities from 486 scientific experts 
and 245 stakeholder organisations across Europe (see Table 1 for a list of stakeholder groups). 
Survey participants rated each priority on a 10-point scale for their relative i) Relevance (i.e. 
likelihood that the advance results in an effective intervention to improve mental health); and ii) 
Feasibility in Europe (i.e. likelihood that the advance can be achieved in Europe). There was strong 
agreement about the most highly rated between different stakeholders, albeit the order was slightly 
different. The final list contains the 6 priorities reported in this paper.  
The process of prioritisation was based on input from over 1000 expert researchers and stakeholder 
organisations. For comparison, the prioritisation exercise used to determine the Global Challenges in 
Mental Health involved only 422 individuals53 and, unlike ROAMER, did not include service users. 
This breadth of input together with the comprehensive and systematic mapping process make this 
project the most inclusive and comprehensive prioritisation process in mental health research to 
date. 
The output of this consensus-based decision-making process has been 6 over-arching research 
priorities that are targeted, actionable, built on excellent European science. Moreover, research 
dedicated to these priority areas would result in a dramatic reduction of the costs and burdens 
associated with mental health in Europe within the next five to ten years. These priorities are shown 
in Table 2, where the numbering of priorities does not reflect any ranking.  
[Table 2 about here] 
 
Where Next? 
Many issues highlighted by ROAMER will be familiar to individuals who are concerned with mental 
health for either personal or professional reasons. Other governments and scientific communities 
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have developed priorities for mental health – including the World Health Organisation53 and the 
National Institute for Mental Health in the USA54. There is some overlap with the ROAMER priorities 
and those of the past – for instance in recommending the development of new interventions and 
conducting lifespan and aetiological research. However, the content of the ROAMER priorities differs 
in meaningful ways – not least in the prominence of priorities relating to reducing stigma, involving 
stakeholders in research, taking account of social, cultural and economic contexts, comorbidity and 
eHealth applications. We expect that these additions reflect the input from service users and other 
stakeholders in ROAMER and of course the technological advances and scientific understandings 
gained over the last ten years.  
There are two main contemporary differences in the current landscape of mental health which make 
the ROAMER research priorities both particularly urgent and ready for translation, and which may 
promote their imminent uptake by researchers and decision-makers.  
The first is that the costs of mental disorder have risen and are set to continue rising – inaction on 
evidence-based mental health policy is simply no longer an option. ROAMER’s priorities are in part 
similar to those we have faced for the last 10 years and could and should have been answered 
decades ago but poor investment and a lack of coordinated research strategy have hampered the 
evidence-gathering. A boost to investment in mental health research can help to resolve research 
questions, inform policy, improve mental health care and in the longer term reduce their burden to 
individuals, families and society. In particular, there needs to be an increase in government funding 
at both national and European levels for mental health research, in order to address the current 
shortfall compared to the cost that mental disorders pose to European society.   
The second issue is that infrastructure now exists in Europe to address issues in mental health in a 
way that simply was not previously possible. Open publication, data policies and European Research 
Networks mean that for the first time there is a real opportunity to develop shared databases and 
international networks. Genome-wide association studies and next generation sequencing (e.g. 
whole exome/whole genome sequencing) are now quick and inexpensive enough that systematic 
identification of biomarkers to drive treatment development is a real possibility35.  
Research questions identified by ROAMER are closely aligned with Horizon 2020 priorities in 
‘personalised care’ – mental health care that takes account of individual variation in and between 
service users in terms of care, diagnosis and service provision. ROAMER’s priorities for preventative 
measures have also been advocated by the European Parliament40 and the European Commission 
(notably, in the identification of the particular importance of “Effective health promotion, disease 
prevention, preparedness and screening” in Horizon 202041) and in many European countries. 
Scientists now have a coordinated and highly applicable research strategy from the ROAMER project. 
We now need to encourage them to engage with policymakers and funders to implement it. By 
making timely use of the resources that Europe has at its disposable, European researchers will be 
able to address some of the huge societal challenges that mental disorders currently represent.   
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Table 1. Overview of ROAMER Scientific Work Packages and Advisory Boards 
 
 
 
 
 Name Topic/Function Members 
Scientific work 
packages 
WP4 Biomedical research  
Scientific experts from a 
variety of backgrounds 
(e.g. neuroscience, 
psychology, psychiatry, 
economics, sociology, 
medicine, social policy 
etc.). Some experts held 
dual roles (e.g. as clinician-
researchers, service users 
etc.) 
WP5 Psychological research and 
treatments 
WP6 Research into social and 
economic issues 
WP7 Public health research 
WP8 Well-being research 
Clinical Research Task 
Force 
Clinical research 
Other work 
packages to 
conduct mappings 
or generate 
priorities 
WP2 Geographic, multidisciplinary 
and lifespan research 
Scientific experts from a 
variety of backgrounds.  
Some experts held dual 
roles (e.g. as clinician-
researchers, service users 
etc.) 
WP3 Research funding, 
infrastructures and capacity 
building 
Other work 
packages 
WP1 Coordination and project 
management 
 
WP9 Coordination of stakeholder 
involvement 
 
WP10 Dissemination of results  
WP11 Report writing  
Advisory Boards Scientific Advisory 
Board 
External scientific and 
methodological advice and 
guidance 
World-wide renown 
scientific experts covering 
all areas within the mental 
health field, not involved 
in ROAMER work packages 
 Stakeholder Advisory 
Board 
Direction and input from non-
academic stakeholders, 
coordinated by Work Package 
9 
Representatives of 
European associations of 
Service users, families and 
carer groups; psychiatrists; 
other health or mental 
health professionals; social 
workers; public health 
sector; policymakers; 
funders 
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Table 2. The six research priorities for policy action in mental health and well-being research 
Research Priority Illustrative Actions/Research Questions 
1. Research into mental disorder prevention, mental health 
promotion and interventions in children, adolescents and 
young adults 
 To perform and sustain long-term prospective cohort studies on the determinants of mental health 
and well-being to study risk and protective factors for mental disorders 
 Developing pharmacological and psychological treatments for children and adolescents 
 How can mental health promotion and social exclusion prevention in schools be improved? 
 Does prevention of depression among pregnant women protect against later mental disorder or 
dysfunction (e.g. depression) among children? What are the cost-benefits?  
 Longitudinal observational studies to analyse the effects of intense use of new media in early age 
and adolescence on later emotional and cognitive competence 
 
2. Focus on the development and causal mechanisms of 
mental health symptoms, syndromes and well-being across 
the lifespan (including older populations) 
 Identification of factors underlying co- and multi-morbidity, extending aetiopathogenic research 
on single disorders to typical comorbid constellations  
 What are the functional characteristics of neurobehavioural mechanisms across the lifespan? 
 To determine what social and biological factors underlie risk or resilience factors for mental 
disorders across the life span 
 To study the effects of financial crises on mental health 
 How do vulnerabilities and stress influence critical developmental trajectories for poor health and 
specific mental disorders across the lifespan (but particularly in childhood and adolescence)? 
 To study what brain abnormalities predict future mental disorder using longitudinal structural and 
functional neuroimaging 
 
3. Developing and maintaining international and 
interdisciplinary research networks and shared databases 
 Increase the number, quality and efficiency of international and interdisciplinary networks 
 Multidisciplinary training programmes for mental health research across different countries 
 Implementation of standardised European research outcomes, databases and terminology for 
mental health and well-being research 
 Establish access to European mental health databases across different studies with standardised 
mental health outcomes 
 
4. Developing and implementing better interventions using 
new scientific and technological advances 
 Strengthening research on new approaches and technology for mental health promotion, disorder 
prevention, mental healthcare and social service delivery  
o Testing the value of internet-based treatments as automated versions of standard 
psychological treatments in specialised mental health care, in “indicated” prevention and 
for use in  primary care settings in particular 
17 
 
o Testing ‘real time’ psychometric feedback over the course of treatment (supported by 
modern software) to adapt dosage and intensity of treatment to service users’ complexity 
and problem profile in order to promote better outcomes 
o To examine acceptability and adherence of eHealth treatments (e.g. for depression), the 
clinical improvement at one-year follow-up, and the cost-effectiveness of the intervention 
in comparison with conventional psychological therapies 
 Understanding why some individuals do not respond to treatment by identifying relevant, and 
potentially developmentally specific, mediating and moderating variables of evidence-based 
psychotherapies for youths with mental disorders 
 
5. Reducing stigma, empowering service users and carers in 
decisions about mental health research 
 How might carers and family members of people with mental health problems perceive and 
experience stigma by association? 
 What are the best methods for measuring and valuing unpaid care? 
 What are the most cost-effective elements of anti-stigma interventions? 
 Studying the role of stigma in the wider context of inequalities (health inequalities, etc.) and 
implement interventions to assess the place of stigma in public services 
 Establish better national or local interventions to address stigma, social exclusion and 
discrimination by carefully defining the essential questions (i.e. who should be targeted? how?, by 
whom?, when?) and to determine how they can be evaluated and by whom 
 
6. Health and social systems research that addresses quality of 
care and takes account of socio-cultural and socio-economic 
contexts and approaches 
 Investigating the impact of differences in the organisation and delivery of national healthcare 
systems on well-being of individuals with mental disorders and carers 
 Health-systems-level research on the cost-effectiveness of different ways of financing, regulating, 
organising and providing services to promote and protect mental health 
 Designing and evaluating methods to assess outcomes from mental health services that can be 
easily and reliably implemented 
 
 
